A rapid pathway for diagnosing heart attacks in the emergency department (ED) was as safe as a slower pathway but neither ...
Many breast cancer survivors whose treatment caused them to develop problems with their heart function can safely stop their ...
Atherosclerosis, the process underlying most cardiovascular diseases, begins long before the first symptoms appear.
The investigational anti-interleukin-6 (IL-6) monoclonal antibody pacibekitug produced sustained reductions in ...
Silent atherosclerosis was detectable from early adulthood and showed sex-specific patterns of growth with age, according to ...
The U.S. Food and Drug Administration (FDA) has approved daraxonrasib for patients whose pancreatic cancer has spread to ...
Antiplatelet monotherapy reduced bleeding but dual therapy provided greater cardiovascular event protection in patients at ...
Milvexian did not reduce major adverse cardiovascular events compared with placebo after a recent acute coronary syndrome and ...
Potent antiplatelet therapy increased bleeding without signs of benefit regarding cardiovascular events in patients with ...
Monotherapy using prasugrel failed to show noninferiority compared with potent antiplatelet therapy plus aspirin at the time ...
Atorvastatin reduced major cardiovascular events by 30% in older people without known cardiovascular disease, diabetes or ...
Prasugrel reduced major cardiovascular events to the same extent as ticagrelor but with lower major bleeding after coronary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results